TICKERNERD
Menu
IMDXIMDXHealthcare · Diagnostics & Research

IMDX Stock Forecast: Insight Molecular Diagnostics, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$4.32
−0.46% on the day

The 5 Wall Street analysts covering Insight Molecular Diagnostics, Inc. hold a median 12-month price target of $9 — +108.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 39 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$142.0M
Ticker Nerd rank
39 / 100
Median analyst target
$9.00
Analysts covering
5
Revenue$32K
Operating income−$10.3M
Net income−$4.3M
Free cash flow−$8.3M
Quarterly, 8 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+1.2%
1M
−8.9%
YTD
−42.4%
1Y
+66.8%
From 52W high
−49.1%
From 52W low
+74.9%
$2.47
$8.48
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

IMDX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Insight Molecular Diagnostics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
39 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
88
Size
72
Momentum
70
Issuance
50
Growth
45
Revisions
36
Volatility
30
Value
29
Quality
8

Accruals (88): Reported profit is backed by cash, and the company is not expanding recklessly.

Quality (8): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

IMDX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IMDX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00$10.00$12.00Oct 25Jan 26Apr 26Jul 26IMDXHigh $12.00Median $9.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
3 Buy2 Hold0 Sell
Low $4.00Median $9.00High $12.00

The green dot is the last close — the median target sits +108.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
24 Aug 2026LUCID CAPITAL MARKETSInitiatesBuy$8.00
18 Aug 2026NeedhamReiteratesBuy$9.00
17 Feb 2026Lake StreetMaintainsBuy—
17 Feb 2026Lake StreetMaintainsBuy$8.00 → $12
11 Nov 2025NeedhamMaintainsBuy—
18 Aug 2025NeedhamReiteratesBuy—
21 May 2025Lake StreetMaintainsBuy—
13 May 2025NeedhamReiteratesBuy—
8 Apr 2025NeedhamReiteratesBuy—
28 Mar 2025Lake StreetInitiatesBuy—
26 Mar 2025Stephens & Co.ReiteratesEqual-Weight—
25 Mar 2025NeedhamReiteratesBuy—
25 Mar 2025Stephens & Co.ReiteratesEqual-Weight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IMDX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

IMDX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Aug 2026, Insight Molecular Diagnostics, Inc. returned +66.8% against +19.6% for the S&P 500, dividends included.

IMDX vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300Oct 25Jan 26Apr 26Jul 26IMDXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

IMDX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Insight Molecular Diagnostics, Inc. (IMDX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.6×

Cheaper than 86% of US stocks

Price / sales
85.0×

Cheaper than 4% of US stocks

Price / book
−13.9×

Cheaper than 98% of US stocks

EV / EBITDA
−3.7×

Cheaper than 76% of US stocks

Growth & margins
Revenue growth (YoY)
−53.9%

Higher than 5% of US stocks

Earnings growth (YoY)
—
Gross margin
46.9%

Higher than 59% of US stocks

Operating margin
−3815.1%

Higher than 3% of US stocks

Net margin
56.7%

Higher than 97% of US stocks

Returns & dividend
Return on equity
159.6%

Higher than 98% of US stocks

Return on assets
−57.8%

Higher than 6% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Insight Molecular Diagnostics, Inc. (IMDX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Insight Molecular Diagnostics, Inc. has a market value of $142.0M and an enterprise value of $126.9M.

  • Revenue in the twelve months to 31 Mar 2026: $1.9M. The latest quarter shrank 53.9% year on year.

  • Net income over the same four quarters: −$47.8M, a −2454.6% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.48.

  • Free cash flow in the twelve months to 31 Mar 2026: −$27.5M, after $3.5M of capital spending.

  • Shares outstanding: 32.3M.

  • Trailing P/E: −2.6×; forward P/E: −5.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Insight Molecular Diagnostics, Inc. employs 55 people — $35K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 25 Aug 2026

Data provided by Twelve Data

Peers

IMDX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
IMDXInsight Molecular Diagnostics, Inc.$142.0M
39
QUCYQuantum Cyber NV$109.3M
6
XGNExagen, Inc.$190.5M
66
BDSXBiodesix, Inc.$275.8M
87
MYGNMyriad Genetics, Inc.$299.2M
52
PRPOPrecipio, Inc.$53.3M
52
FLGTFulgent Genetics, Inc.$565.2M
46

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Insight Molecular Diagnostics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest IMDX news & analysis

Insight Molecular Diagnostics Inc. (IMDX) Discusses Advances in Heart Transplant Rejection Testing and Evolution of Diagnostic Methods Transcript

Seeking Alpha · 17 Aug 2026neutral

Insight Molecular Diagnostics, Inc. (IMDX) participated in a discussion covering advances in heart transplant rejection testing and the broader evolution of diagnostic methods, as detailed in a Seeking Alpha transcript.

Why it matters — IMDX watchers would care because the discussion highlights the company's involvement in the evolving field of transplant rejection diagnostics, which is central to its product focus.

Insight Molecular Diagnostics to Host Virtual KOL Event on August 17, 2026: Moving Toward In-House Heart Transplanted Organ Rejection Testing

GlobeNewsWire · 11 Aug 2026positive

Insight Molecular Diagnostics announced it will host a virtual key opinion leader event on August 17, 2026, featuring Dr. Max Jacob Liebo alongside iMDx VP of Medical Affairs Nick Ioannou and CEO Josh Riggs, to discuss the company's GraftAssure platform. The event will focus on iMDx's move toward in-house heart transplanted organ rejection testing using digital PCR-based dd-cfDNA monitoring.

Why it matters — The event signals iMDx's progress toward offering in-house testing for transplanted organ health monitoring, a development watchers would track for the company's GraftAssure platform and growth direction.

Insight Molecular Diagnostics Inc. (IMDX) Q2 2026 Earnings Call Transcript

Seeking Alpha · 11 Aug 2026neutral

Insight Molecular Diagnostics, Inc. (IMDX) released the transcript of its second-quarter 2026 earnings call, as published by Seeking Alpha.

Why it matters — The earnings call transcript provides IMDX watchers with the company's own commentary and discussion on its Q2 2026 results.

iMDx to Release Second Quarter Results on August 10, 2026 and Attend Needham Virtual MedTech & Diagnostics 1x1 Conference

GlobeNewsWire · 4 Aug 2026neutral

Insight Molecular Diagnostics, Inc. (iMDx) announced it will report its second quarter 2026 financial results after the market closes on Monday, August 10, 2026. The company also noted it will attend the Needham Virtual MedTech & Diagnostics 1x1 Conference.

Why it matters — IMDX watchers will be able to review the company's Q2 2026 financial performance and hear from management at the upcoming conference.

FAQ

Frequently asked questions about IMDX stock

What is the IMDX stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Insight Molecular Diagnostics, Inc. have a median 12-month price target of $9, with estimates ranging from $4 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IMDX stock a buy right now?

Of the 5 analysts covering Insight Molecular Diagnostics, Inc., 3 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Insight Molecular Diagnostics, Inc. 39 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IMDX?

As at 22 Aug 2026, Insight Molecular Diagnostics, Inc. ranks 39 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (88 of 100).

Will IMDX stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +108.3% from the last close, and Ticker Nerd's factor model ranks Insight Molecular Diagnostics, Inc. 39 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IMDX stock forecast for 2030?

No analyst covering Insight Molecular Diagnostics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IMDX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $12 over the next 12 months.

How has IMDX stock performed over the past year?

Insight Molecular Diagnostics, Inc. returned +66.8% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Insight Molecular Diagnostics, Inc. do?

Insight Molecular Diagnostics Inc. is a precision diagnostics company specializing in the development and commercialization of advanced molecular diagnostic tests for both clinical and research applications.

What is the latest news on IMDX?

The most recent item we track (Seeking Alpha, 17 Aug 2026): "Insight Molecular Diagnostics Inc. (IMDX) Discusses Advances in Heart Transplant Rejection Testing and Evolution of Diagnostic Methods Transcript". Insight Molecular Diagnostics, Inc. (IMDX) participated in a discussion covering advances in heart transplant rejection testing and the broader evolution of diagnostic methods, as detailed in a Seeking Alpha transcript.

Company

About Insight Molecular Diagnostics, Inc.

Insight Molecular Diagnostics Inc. is a precision diagnostics company specializing in the development and commercialization of advanced molecular diagnostic tests for both clinical and research applications. With a core focus on transplant medicine and oncology, the company’s product portfolio includes laboratory-developed tests, kitted research-use-only assays, and kitted clinical tests targeting key unmet needs in patient care. Notable offerings are its VitaGraft Kidney and VitaGraft Liver tests, which use blood-based detection of donor-derived cell-free DNA to monitor for organ transplant rejection, and the GraftAssure suite, which leverages droplet digital PCR technology for highly sensitive transplant monitoring. In the oncology space, Insight Molecular Diagnostics is developing DetermaCNI—a blood-based assay to detect early progression after one cycle of cancer treatment—and DetermaIO, a test predicting response to immunotherapies by assessing the tumor microenvironment. The company also engages in biomarker discovery, assay development, and supports clinical trials for pharmaceutical partners. Through collaboration with industry leaders such as Bio-Rad Laboratories, Insight Molecular Diagnostics contributes to both research and in-vitro diagnostic advancements. Founded in 2009 and now headquartered in Nashville, Insight Molecular Diagnostics plays a significant role in improving patient outcomes across the healthcare landscape by enabling personalized and real-time intervention through precision diagnostics.

CEO Mr. Joshua Riggs · 55 employees · United States · https://www.imdxinc.com